The Effects of Anesthetics on Brain Network Connectivity in Patients With Supratentorial Glioma

NCT ID: NCT06138340

Last Updated: 2025-02-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-08-31

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Perioperative anesthesia can affect postoperative cognitive function. In our previous study, intraoperative dexmedetomidine (Dex) infusion reduced the incidence of delirium within the first 5 days after brain tumor. However, the mechanism is still unclear. With the development of neuroimaging, multimodal neuroimaging technology provide a new method to explore the underlying mechanism. Therefore, the purpose of this study is to analyze the alterations of brain network under sedation and anesthesia by different anesthetics in patients with supratentorial glioma and their association with cognition.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Brain Network Connectivity Postoperative Delirium Dexmedetomidine Propofol

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dex group

Participants will be sedated and maintained by dexmedetomidine.

Dexmedetomidine

Intervention Type DRUG

Participants will be sedated and maintained by dexmedetomidine during the surgery.

Propofol group

Participants will be sedated and maintained by propofol.

Propofol

Intervention Type DRUG

Participants will be sedated and maintained by propofol during the surgery.

Remimazolam group

Participants will be sedated and maintained by remimazolam.

Remimazolam Injection

Intervention Type DRUG

Participants will be sedated and maintained by remimazolam during the surgery.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexmedetomidine

Participants will be sedated and maintained by dexmedetomidine during the surgery.

Intervention Type DRUG

Propofol

Participants will be sedated and maintained by propofol during the surgery.

Intervention Type DRUG

Remimazolam Injection

Participants will be sedated and maintained by remimazolam during the surgery.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed as unilateral supratentorial glioma by MRI
* Selective operation
* Age over 18 years old
* ASA I-II
* Right handedness

Exclusion Criteria

* History of cerebrovascular disease, brain trauma, chemotherapy and radiotherapy, or psychotropic drugs
* History of intracranial surgery
* Drug and/or alcohol abuse
* History of dementia or mental illness
* Pregnant or lactating women
* Contraindications for MRI
* Severe bradycardia (heart rate less than 40 beats per minute), sick sinus syndrome or second-to-third degree atrioventricular block
* Severe hepatic or renal dysfunction
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beijing Tiantan Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yuming Peng

Deputy chief of Department of Anesthesiology

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Beijing Tian Tan Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yuming Peng, MD,Ph.D

Role: CONTACT

8610-59976658

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yuming Peng

Role: primary

8610-59976658

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20230808

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Dexmedetomidine Effect on Delirium of Elderly Patients
NCT06111300 NOT_YET_RECRUITING PHASE4